Summit Therapeutics Inc. (SMMT)
| Market Cap | 14.17B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -921.62M |
| Shares Out | 771.15M |
| EPS (ttm) | -1.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,313,305 |
| Open | 17.39 |
| Previous Close | 17.25 |
| Day's Range | 17.32 - 19.05 |
| 52-Week Range | 15.55 - 36.91 |
| Beta | -1.53 |
| Analysts | Buy |
| Price Target | 33.63 (+83.07%) |
| Earnings Date | Oct 20, 2025 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SMMT stock is "Buy." The 12-month stock price target is $33.63, which is an increase of 83.07% from the latest price.
News
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript
Don't Buy Summit Therapeutics Until This Big Thing Happen
Summit Therapeutics plans to file for a key FDA approval by the end of this year. The drugmaker is betting that the FDA will change its mind on guidance already handed down.
Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
2 Monster Stocks in the Making to Buy and Hold
SoFi Technologies could become the dominant banking model in the future. Summit Therapeutics is developing a drug with incredible sales potential.
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying
I'm rating Summit Therapeutics a 'cautious Buy' based on the promising dual-action lung cancer therapy Ivonescimab and significant insider buying. SMMT's Ivonescimab targets non-small cell lung cancer...
Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript
Summit Therapeutics Inc. ( SMMT) Jefferies London Healthcare Conference 2025 November 18, 2025 10:30 AM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, C...
Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript
Summit Therapeutics Inc. ( SMMT) UBS Global Healthcare Conference 2025 November 10, 2025 3:30 PM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Di...
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results f...
Summit Therapeutics to Present at Upcoming Investor Conferences
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferenc...
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in China and spo...
1 Monster Stock in the Making to Buy and Hold
Summit Therapeutics' ivonescimab continues to ace phase 3 studies against approved drugs. The investigational cancer medicine could eventually become one of the world's best-selling therapies.
Summit Therapeutics: A Risky Bet in the Biotech Arena?
Explore the exciting world of Summit Therapeutics (SMMT +2.83%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into m...
Summit Therapeutics Raises $500 Million in Private Placement
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech institut...
Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2025 Earnings Call October 20, 2025 8:00 AM EDT Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West Mahkam Zanganeh - Co...
Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold
Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically significant overall survival data. SMMT faces heightened financing risk due to increa...
What's Going On With Summit Therapeutics Stock On Monday?
Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results.
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the ...
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsore...
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, p...
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, ...
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the grant of inducement awards of options to purchase a collective total of...
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponso...
Ten Bull Market 10-Baggers
While broad market performance has been robust, one striking aspect of this cycle has been the extraordinary gains in a handful of individual equities. Ten stocks in the large-cap Russell 1,000 have n...
Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential
Summit Therapeutics Inc. (SMMT) is a U.S.-based biopharmaceutical company. It focuses on developing innovative medicines for cancer treatment.
Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. investors ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm has initiated an inv...